Wolverine Trading’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-6,400
Closed -$306K 3995
2022
Q3
$306K Sell
6,400
-4,000
-38% -$213K ﹤0.01% 3129
2022
Q2
$512K Buy
+10,400
New +$529K ﹤0.01% 2522
2022
Q1
Sell
-4,700
Closed -$387K 5394
2021
Q4
$387K Buy
4,700
+700
+18% +$60K ﹤0.01% 3797
2021
Q3
$377K Buy
4,000
+1,900
+90% +$192K ﹤0.01% 4361
2021
Q2
$205K Sell
2,100
-1,900
-48% -$166K ﹤0.01% 4986
2021
Q1
$318K Buy
+4,000
New +$377K ﹤0.01% 4390
2020
Q4
Sell
-4,000
Closed -$277K 4807
2020
Q3
$277K Buy
+4,000
New +$284K ﹤0.01% 3486
2019
Q1
Sell
-11,100
Closed -$452K 4526
2018
Q4
$452K Buy
+11,100
New +$579K ﹤0.01% 2729
2017
Q1
Sell
-27,700
Closed -$1.11M 4253
2016
Q4
$1.11M Buy
+27,700
New +$1.18M 0.01% 1826
2016
Q3
Sell
-27,700
Closed -$1.06M 4591
2016
Q2
$1.06M Buy
+27,700
New +$1.19M 0.01% 1542

Other funds holding BIB

Wolverine Trading's BIB Position: Q1 2017 in Review

Wolverine Trading sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2017, closing a stake of 6,874 shares — an estimated $274K sold.

Wolverine Trading first reported a position in BIB in Q4 2016 and held it in 1 quarter. The position peaked at $274K in Q4 2016. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2017.

  • Wolverine Trading reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2017 after selling out during the quarter.
  • Wolverine Trading sold 6,874 ProShares Ultra NASDAQ Biotechnology shares in Q1 2017, an estimated $274K.
  • Wolverine Trading first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 1 quarter.
  • Wolverine Trading's ProShares Ultra NASDAQ Biotechnology position peaked at $274K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2017.

Based on Wolverine Trading's 13F filing for Q1 2017, filed 15 May 2017.